Company intelligence / Profile preview

Maxiom Group

Cambridge, United Kingdom

Ownership: Private
Development stage: Other

Overview

Maxion Therapeutics is developing a proprietary pipeline of KnotBody® molecules targeting ion channel- and GPCR-driven diseases, with lead program MAX001 in preclinical development for inflammatory diseases.[1][2]

Therapeutic areas: ImmunologyCardiovascularNeurologyDermatologyGastroenterology
Modalities: KnotBodyProtein
Industry: Biotech

Beyond the preview

Go deeper on Maxiom Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxiom Group.

Explore the full profile